Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
27°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
16.39
+1.00 (+6.50%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neogenomics Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
The Implications Behind Genetron Health's Latest Earnings Report
December 08, 2021
Genetron Holdings Limited (NASDAQ: GTH) recently announced its latest fiscal report, elaborating its progress in the oncology genetic testing industry. The China-based company provides early tumor...
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 07, 2021
Gainers PLx Pharma (NASDAQ:PLXP) stock in...
Via
Benzinga
Analyst Ratings For NeoGenomics
December 07, 2021
Within the last quarter, NeoGenomics (NASDAQ:NEO) has observed the following...
Via
Benzinga
The Implications Behind Genetron Health's Latest Earnings Report
December 03, 2021
Image provided by Mentor Finance Genetron Holdings Limited (NASDAQ: GTH) recently announced its latest fiscal report, elaborating its progress in the oncology genetic testing...
Via
Benzinga
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
November 30, 2021
FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Where NeoGenomics Stands With Analysts
November 05, 2021
Over the past 3 months, 4 analysts have published their opinion on NeoGenomics (NASDAQ:
Via
Benzinga
Recap: NeoGenomics Q3 Earnings
November 04, 2021
NeoGenomics (NASDAQ:NEO) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
NASDAQ: NEO Shareholder Notice: Investigation over Potential Wrongdoing at NeoGenomics, Inc.
November 29, 2021
San Diego, CA -- (SBWIRE) -- 11/29/2021 -- An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ: NEO) shares over potential wrongdoing at NeoGenomics, Inc. was announced.
Via
SBWire
Exposures
COVID-19
NASDAQ:NEO Investor Notice: Investigation over Possible Securities Laws Violations by NeoGenomics, Inc.
November 10, 2021
San Diego, CA -- (SBWIRE) -- 11/10/2021 -- NeoGenomics, Inc. is under investigation concerning possible violations of securities laws in connection with certain financial statements.
Via
SBWire
Exposures
COVID-19
NeoGenomics Appoints Dave Daly to Its Board of Directors
November 10, 2021
FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics, inc (NEO) Q3 2021 Earnings Call Transcript
November 06, 2021
NEO earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
NeoGenomics Reports Revenue of $121 Million in the Third Quarter
November 04, 2021
Third-Quarter 2021 Results and Highlights: - Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million - Consolidated...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
Exposures
COVID-19
Legal
Pension
Recap: NeoGenomics Q2 Earnings
August 06, 2021
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01),...
Via
Benzinga
81 Biggest Movers From Yesterday
November 05, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...
Via
Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
November 04, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...
Via
Benzinga
NeoGenomics Announces Leadership Team Transition
November 04, 2021
FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
October 19, 2021
Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:
Via
Benzinga
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
October 13, 2021
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics Announces Board of Directors' Transition
October 12, 2021
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT....
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
Exposures
COVID-19
Legal
Pension
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
October 04, 2021
Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people...
Via
Benzinga
Why Guardant Health Is Down More Than 14% Friday
October 01, 2021
Investors aren't fans of an acquisition the diagnostics company is rumored to be considering.
Via
The Motley Fool
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
October 01, 2021
Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar...
Via
Benzinga
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
September 09, 2021
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
September 01, 2021
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Earnings Scheduled For August 12, 2021
August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...
Via
Benzinga
NeoGenomics, inc (NEO) Q2 2021 Earnings Call Transcript
August 06, 2021
NEO earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
NeoGenomics Q2 Earnings Helped By Higher Test Volume; Backs FY21 Guidance
August 06, 2021
NeoGenomics Inc (NASDAQ: NEO) reported Q2 revenue of $122 million, +40% Y/Y, beating the consensus of $118.16 million. Clinical Services revenue of $101 million...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.